Protocol Ledger

NCT03386721 · Phase II · TERMINATED

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Interventional Phase II clinical trial protocol NCT03386721 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-02-19 Enrollment: 256 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03386721
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)256 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03386721
Protocol FieldVerified Registry Value
NCT IdentifierNCT03386721
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment256 participants (ACTUAL)
Registered Start Date2018-02-19
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03386721
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
UZ AntwerpenEdegem, BelgiumOpen Hospital Dossier ->
UZ GentGhent, BelgiumOpen Hospital Dossier ->
Institut BergonieBordeaux, FranceOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI